Fortekor Plus (20 - 40 kg)

1 x 30 pc

Tablet

Active substance

Benazepril (Benazepril hydrochloride) : 10 mg

Pimobendane : 5 mg

ATC code

QC09BX90 Benazepril and pimobendan

QC09BX ACE inhibitors, other comb.

QC09B ACE inhibitors, comb.

QC09 Agents acting on the renin-angiotensin system

QC Cardiovascular system

Species

Dogs.

Indications

For the treatment of congestive heart failure due to atrioventricular valve insufficiency or dilated cardiomyopathy in dogs. FORTEKOR PLUS is a fixed dose combination and should only be used in patients whose clinical signs are successfully controlled by administration of the same doses of the individual components (pimobendan and benazepril hydrochloride) given concurrently.

Dose to be administered and administration route

Oral use.

Dose and treatment schedule:

FORTEKOR PLUS is a fixed combination product which should only be used in dogs which require both active substances to be administered concomitantly at this fixed dose.

The recommended dose range for FORTEKOR PLUS is 0.25–0.5 mg pimobendan per kg body weight and 0.5–1 mg benazepril hydrochloride per kg body weight divided into two daily doses. FORTEKOR PLUS tablets should be administered orally, twice daily 12 hours apart (morning and evening) and approximately 1 hour before feeding.

The tablets are breakable along the score line. The table below may be used for guidance.

	Strength and number of tablets to be
Body weight (kg) of dog	administered
	FORTEKOR PLUS 5 mg/10 mg tablets
	Morning	Evening
10 – 20	0.5	0.5
20 – 40	1	1
Over 40 kg	2	2

Adverse reactions

Pimobendan

A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and can be avoided by reducing the dose in those cases.

Transient diarrhoea, anorexia or lethargy have been observed in rare cases.

Benazepril hydrochloride

Transient vomiting, incoordination or signs of fatigue have been reported in dogs very rarely, during post authorization experience. In dogs with chronic kidney disease, benazepril may increase plasma creatinine concentrations at the start of therapy very rarely. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated)

- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)

- rare (more than 1 but less than 10 animals in 10,000 animals treated)

- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).